Chlamydia pneumoniae induces a pro-inflammatory phenotype in murine vascular smooth muscle cells independently of elevating reactive oxygen species

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 3, 2012, Pages 218-226

  Rivera, Jennifer ^a,b   Walduck, Anna K ^b   Strugnell, Richard A ^b   Sobey, Christopher G ^a   Drummond, Grant R ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bacterial infection; NADPH oxidase; Reactive oxygen species

Indexed keywords

APOCYNIN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; BACTERIAL VIRULENCE; CELL STRAIN HEPG2; CHLAMYDIAL PNEUMONIA; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; REACTIVE OXYGEN SPECIES;

EID: 84857430422     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05657.x     Document Type: Article

References (39)

1. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
2. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S. Afr. Med. J. 1992; 82: 158-61.
3. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler. Thromb. 1993; 13: 1501-4.
4. Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of Chlamydia pneumoniae infection in the athersclerotic carotid artery. Stroke 1998; 29: 773-8.
5. Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Cardiovasc. Res. 2002; 56: 269-76.
6. -/- mouse model within six months. Mol. Cell. Biochem. 2000; 215: 123-8.
7. Rothstein NM, Quinn TC, Madico G, Gaydos CA, Lowenstein CJ. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J. Infect. Dis. 2001; 183: 232-8.
8. Muhlestein JB, Anderson JL, Hammond EH et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
9. Campbell LA, Kuo CC. Chlamydia pneumoniae: An infectious risk factor for atherosclerosis? Nat. Rev. Microbiol. 2004; 2: 23-32.
10. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ. Res. 2001; 89: 244-50.
11. Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH. Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J. Surg. Res. 2000; 90: 76-81.
12. Yang X, Coriolan D, Schultz K, Golenbock DT, Beasley D. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2308-14.
13. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007; 87: 245-313.
14. Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: Insights from transgenic and knockout mouse models. Redox Rep. 2010; 15: 50-63.
15. Grandvaux N, Soucy-Faulkner A, Fink K. Innate host defense. Nox and Duox on phox's tail. Biochimie 2007; 89: 1113-22.
16. Huang J, Canadien V, Lam GY et al. Activation of antibacterial autophagy by NADPH oxidases. Proc. Natl Acad. Sci. USA 2009; 106: 6226-31.
17. 2+ ATPase-4 in the vascular smooth muscle cell cycle. Am. J. Physiol. Cell Physiol. 2003; 285: C88-95.
18. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann. Intern. Med. 1996; 125: 979-82.
19. Dechend R, Gieffers J, Dietz R et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003; 108: 261-5.
20. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol. 1994; 11: 95-102.
21. Heumuller S, Wind S, Barbosa-Sicard E et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008; 51: 211-7.
22. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc. Res. 2005; 65: 495-504.
23. Lassegue B, Sorescu D, Szocs K et al. Novel gp91 (phox) homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ. Res. 2001; 88: 888-94.
24. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 812-9.
25. Wang HD, Xu S, Johns DG et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ. Res. 2001; 88: 947-53.
26. Kalinina N, Agrotis A, Tararak E et al. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 2037-43.
27. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008; 120: 254-91.
28. - and systolic blood pressure in mice. Circ. Res. 2001; 89: 408-14.
29. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011; 10: 453-71.
30. Banfi B, Clark RA, Steger K, Krause KH. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J. Biol. Chem. 2003; 278: 3510-3.
31. Brandes RP, Miller FJ, Beer S et al. The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic. Biol. Med. 2002; 32: 1116-22.
32. Miller AA, Drummond GR, Schmidt HHHW, Sobey CG. NADPH-oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ. Res. 2005; 97: 1055-62.
33. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: From cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. 1994; 58: 686-99.
34. Hammerschlag MR. The intracellular life of chlamydiae. Semin. Pediatr. Infect. Dis. 2002; 13: 239-48.
35. 2+ dependent reactive nitrogen and oxygen species. J. Infect. 2003; 46: 120-8.
36. Brandes RP, Viedt C, Nguyen K et al. Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb. Haemost. 2001; 85: 1104-10.
37. 2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells. Role of Rac1 and NADPH oxidase. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H1001-7.
38. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004; 84: 1381-478.
39. Chen C, Chai H, Wang X, Lin PH, Yao Q. Chlamydia heat shock protein 60 decreases expression of endothelial nitric oxide synthase in human and porcine coronary artery endothelial cells. Cardiovasc. Res. 2009; 83: 768-77.